Qisda Group announced on 18th January that its Board of Directors has approved the application for a listing and IPO in Hong Kong through its subsidiary BenQ BM Holding Cayman Corp., which will be proposed for approval at the first annual shareholder meeting on 14th March 2024.  

BenQ Medical Center currently owns two major teaching hospitals, Nanjing BenQ Medical Center and Suzhou BenQ Medical Center, and has invested in a hospital in Guangxi. The medical centre is the largest business unit within Qisda Group and spearheads Qisda's operation in the healthcare industry.

According to Qisda, the listing and IPO will enable BenQ Medical Center to raise funds from diversified sources to strengthen its capital and optimise its financial structure, with a view to further expanding the hospital's scale, increasing the number of hospital beds and introducing specialised medical teams and equipment.

In addition, the listing and IPO will also effectively enhance the visibility of Qisda Group in the healthcare business and attract more talents, which will be conducive to increasing the Group's revenue and profitability, and is expected to accelerate the growth momentum for future operations and pursue the best interests of shareholders.

According to sources, the IPO will be priced at US$1 per share. The number of new shares is expected to represent approximately 10-25% of the group's total shareholding after the issue, which will result in a reduction of Qisda's shareholding in BenQ Medical Center by 9.5-23.75%.